BioCentury
ARTICLE | Company News

Molecular Partners CEO Zahnd to take medical leave

March 11, 2015 1:34 AM UTC

Molecular Partners AG (SIX:MOLN) said CEO Christian Zahnd will soon take temporary medical leave. In the interim, COO Patrick Amstutz and Chairman Jorn Aldag will take over Zahnd's responsibilities.

Molecular Partners raised CHF98.6 million ($102.2 million) in an IPO on the SIX Swiss Exchange in November. It was the fourth European company to raise more than $100 million in an IPO in 2014 (see BioCentury Extra, Nov. 5, 2014). ...